The past, present, and future of liver cancer research in China
Cancer Letters · 2023-10 · 574 · 216334
DOI: 10.1016/j.canlet.2023.216334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2023-10. Verfasst von Lichao Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, National Natural Science Foundation of China, Beijing, 100085, PR China; State Key Laboratory of Molecular Oncology, N…. Hauptthemen laut MEDLINE: Liver Neoplasms, Translational Research, Biomedical. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Liver cancer is among the leading causes of cancer-related death worldwide and China accounts for nearly half of the global burden of liver cancer. Effective interventions such as hepatitis vaccinations, new blood tests and imaging tests significantly decreased the incidence worldwide, especially in China. Unraveling the systemic and molecular mechanisms of liver cancer would contribute to develop more effective therapies to prolong the 5 year survival of the patients. The Chinese funding agencies have been paying high attention to the basic and translational research of liver cancer. Over the last decade, the National Natural Science Foundation of China (NSFC) initiated a panel of research programs which supported liver cancer research in multiple directions. Besides, great progress has been made in basic and clinical research, platform construction and drug development in the field of liver cancer. In this article, we summarized the funding landscape, research progress, cooperation among countries and institutions, and drug discovery in China, with an attempt to compare the status and outcome with our peers globally.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Health Sciences, National Natural Science Foundation of China, Beijing, 100085, PR China; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Can…
- Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100020, PR China. Electronic address: yang.yuan@imicams.ac.cn.
- Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100020, PR China. Electronic address: li.yang@imicams.ac.cn.
- Department of Genetics, School of Life Science, Anhui Medical University, Hefei, 230031, Anhui, PR China. Electronic address: liyang@ahmu.edu.cn.
- Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for…
- Department of Health Sciences, National Natural Science Foundation of China, Beijing, 100085, PR China. Electronic address: shirong@nsfc.gov.cn.
Zitieren
APA
Sun, L., Yang, Y., Li, Y., Li, Y., Zhang, B., & Shi, R. (2023). The past, present, and future of liver cancer research in China. Cancer Letters, 574, 216334. https://doi.org/10.1016/j.canlet.2023.216334
Vancouver
Sun L, Yang Y, Li Y, Li Y, Zhang B, Shi R. The past, present, and future of liver cancer research in China. Cancer Letters. 2023;574:216334. doi:10.1016/j.canlet.2023.216334
BibTeX
@article{Sun2023,
author = {Sun, Lichao and Yang, Yuan and Li, Yang and Li, Yang and Zhang, Bin and Shi, Rong},
title = {The past, present, and future of liver cancer research in China},
journal = {Cancer Letters},
year = {2023},
volume = {574},
pages = {216334},
doi = {10.1016/j.canlet.2023.216334}
}
EUVIMED